Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMS6DPF)

• Drug Name: ADPT01 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMS6DPF

Molecule-Related Drug Atlas

Drug(s) Targeting Programmed cell death protein 1 (PD-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nivolumab	DMAB9QE	Melanoma	2C30	Approved	[2]
Tislelizumab	DMGVUO5	Hodgkin lymphoma	2B30	Approved	[3]
MK-3475	DMBYNW0	Melanoma	2C30	Approved	[2]
Pembrolizumab	DMFQEA6	Melanoma	2C30	Approved	[4]
Cemiplimab	DMKMJHE	Cutaneous squamous cell carcinoma	2C30	Approved	[5]
Retifanlimab	DMRKTCP	Neuroendocrine cancer	2B72.1	Approved	[6]
Sintilimab	DMGWR0C	Hodgkin lymphoma	2B30	Approved	[7]
Dostarlimab	DM78NWP	Endometrial cancer	2C76	Approved	[8]
Toripalimab	DMSGA6Z	Demodex blepharitis	1G07	Approved in China	[9]
PDR001	DM53J6B	Melanoma	2C30	Phase 3	[10]

Drug(s) Targeting Lymphocyte activation gene 3 protein (LAG3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Relatlimab	DM28AZV	Melanoma	2C30	Approved	[11]
Anti-LAG3	DMJO402	Gastric adenocarcinoma	2B72	Phase 2	[6]
BMS-986016	DMDCHM7	Hematologic tumour	2B33.Y	Phase 1/2	[12]
IMP-321	DM18ZLW	Allergy	4A80-4A85	Phase 1/2	[13]
Favezelimab	DMYAIE2	Non-hodgkin lymphoma	2B33.5	Phase 1/2	[14]
XmAb22841	DMQB3HD	Solid tumour/cancer	2A00-2F9Z	Phase 1	[15]
FS118	DM0QH9K	Advanced cancer	2A00-2F9Z	Phase 1	[4]
RG6139	DMJFM3O	Solid tumour/cancer	2A00-2F9Z	Phase 1	[16]
IMP-701	DMXSMF9	Solid tumour/cancer	2A00-2F9Z	Phase 1	[17]
GSK2831781	DMC47M9	Autoimmune disease	4A40-4A45	Phase 1	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Lymphocyte activation gene 3 protein (LAG3)	TTNVXAW	LAG3_HUMAN	Inhibitor	[1]
Programmed cell death protein 1 (PD-1)	TTNBFWK	PDCD1_HUMAN	Inhibitor	[1]

References

• [1] Clinical pipeline report, company report or official report of Novartis.
• [2] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [3] Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). Expert Opin Investig Drugs. 2020 Dec;29(12):1355-1364.
• [4] Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
• [5] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Sintilimab: First Global Approval. Drugs. 2019 Feb;79(3):341-346.
• [8] Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. Future Oncol. 2021 Mar;17(8):877-892.
• [9] Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol. 2022 Jan 12;12:730666.
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761234
• [12] Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015 March; 7(2): 85-96.
• [13] A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells. J Immunol. 2007 Sep 15;179(6):4202-11.
• [14] A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer. ESMO Open. 2022 Dec;7(6):100639.
• [15] Clinical pipeline report, company report or official report of Xencor.
• [16] Clinical pipeline report, company report or official report of Genentech.
• [17] IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study. J Immune Based Ther Vaccines. 2007 Mar 29;5:5.